Skip to Main Content

Paper Details

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
J Natl Cancer Inst
71
2018
GBM, GBM PDX, GBM PDX lines, GBM and ovarian cancer PDX, Interferon, JAK, MV-permissive and -resistant GBM PDXs, MV-resistant (, PDX, PDXs, RNA, STAT1/3, Tumors, glioblastoma, hematologic malignancies, human, interferon, measles virus, ovarian cancer, patient, patients, resistance gene signature, ruxolitinib, solid tumors, tumor, tumors, unique gene signature, xenografts
Author NameAffiliation
Ann L ObergMayo Clinic
Caterina GianniniMayo Clinic
Caterina GianniniMayo Clinic
Paul HaluskaMayo Clinic
Saravut J WerohaMayo Clinic
Jann N SarkariaMayo Clinic
  • 1 - 6

Datasets

Release 1.2